ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

12:00PM-1:00PM: Abstract Number: PP11

“Knitting a Community of Hope”- Supporting, Empowering and Educating Those Living with Lupus, and Overlapping Conditions and Their Loved Ones via in Person and Virtual Support Groups That Include Art Therapy, and Wellness Techniques Is Key; Mental Health Is as Important as Physical Health

Patient Perspectives (PP09–PP12)

12:00PM-1:00PM: Abstract Number: PP09

An Integrative Approach to Managing Rheumatoid Arthritis (RA): Healing the Body, Mind & Spirit

Patient Perspectives (PP09–PP12)

12:00PM-1:00PM: Abstract Number: PP12

COVID-19, Racism, and Gender Discrimination: The Function of Stress in Widening the Gap in Health Disparities

Patient Perspectives (PP09–PP12)

12:00PM-1:00PM: Abstract Number: PP10

Patients with Relapsing Polychondritis (“RP”) and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope

Patient Perspectives (PP09–PP12)

3:00PM-3:50PM: Abstract Number: 1522

Biomarkers of Hemodynamic Severity of Systemic-Sclerosis Associated Pulmonary Arterial Hypertension by Serum Proteome Analysis

Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

3:00PM-3:50PM: Abstract Number: 1508

Blood-Brain Barrier Leakage in Systemic Lupus Erythematosus Is Associated with Gray Matter Loss and Cognitive Impairment

SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)

3:00PM-3:50PM: Abstract Number: 1511

Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort

SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)

3:00PM-3:50PM: Abstract Number: 1497

COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance

Reproductive Issues in Rheumatic Disorders (1497–1501)

3:00PM-3:50PM: Abstract Number: 1500

Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation

Reproductive Issues in Rheumatic Disorders (1497–1501)

3:00PM-3:50PM: Abstract Number: 1462

Intensity and Duration of Silica Exposure Increase Rheumatoid Arthritis Risk Among Coal Miners

Epidemiology & Public Health I: RA (1462–1466)

3:00PM-3:50PM: Abstract Number: 1525

Intergenic HLA Variants in African American Patients with Systemic Sclerosis Regulate Expression of HLA-DRB1

Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

3:00PM-3:50PM: Abstract Number: 1524

Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice

Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

3:00PM-3:50PM: Abstract Number: 1509

Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study

SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)

3:00PM-3:50PM: Abstract Number: 1507

Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort

SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)

3:00PM-3:50PM: Abstract Number: 1464

Multi-Variate Approach Including Serology and Genetics for an Improved Identification of Patients at Risk of Developing Rheumatoid Arthritis

Epidemiology & Public Health I: RA (1462–1466)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].